Dafna Capital Management buys $10,096,265 stake in NxStage Medical (NXTM)

NxStage Medical (NXTM) : Dafna Capital Management scooped up 30,000 additional shares in NxStage Medical during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 396,554 shares of NxStage Medical which is valued at $10,096,265.NxStage Medical makes up approximately 7.97% of Dafna Capital Management’s portfolio.

Other Hedge Funds, Including , Two Sigma Advisers Lp reduced its stake in NXTM by selling 20,900 shares or 7.65% in the most recent quarter. The Hedge Fund company now holds 252,387 shares of NXTM which is valued at $6,425,773. NxStage Medical makes up approx 0.03% of Two Sigma Advisers Lp’s portfolio.Alliancebernstein boosted its stake in NXTM in the latest quarter, The investment management firm added 16,100 additional shares and now holds a total of 109,310 shares of NxStage Medical which is valued at $2,783,033.William Blair Investment Management reduced its stake in NXTM by selling 5,203 shares or 0.87% in the most recent quarter. The Hedge Fund company now holds 591,298 shares of NXTM which is valued at $15,178,620. NxStage Medical makes up approx 0.06% of William Blair Investment Management’s portfolio.Blair William Coil boosted its stake in NXTM in the latest quarter, The investment management firm added 258,162 additional shares and now holds a total of 1,186,242 shares of NxStage Medical which is valued at $30,450,832. NxStage Medical makes up approx 0.27% of Blair William Coil’s portfolio.

NxStage Medical opened for trading at $22.82 and hit $23.06 on the upside on Thursday, eventually ending the session at $22.865, with a gain of 0.02% or 0.005 points. The heightened volatility saw the trading volume jump to 2,16,524 shares. Company has a market cap of $1,476 M.

On the company’s financial health, NxStage Medical reported $-0.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.04. The company had revenue of $92.20 million for the quarter, compared to analysts expectations of $89.30 million. The company’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.08 EPS.

Many Wall Street Analysts have commented on NxStage Medical. NxStage Medical was Upgraded by Northland Capital to ” Outperform” on Jun 28, 2016.

NxStage Medical Inc. is a medical device company. The Company is engaged in the development manufacturing and marketing of products for the treatment of kidney failure fluid overload and related blood treatments and procedures. The Company’s products include the System One Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles. Its primary product the System One is a small portable easy-to-use hemodialysis system. It is designed to deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller portable easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings including patient homes as well as more traditional care settings such as hospitals and dialysis centers. The Company operates in three reportable business segments: System One In-Center and Services.

Leave a Reply

NxStage Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on NxStage Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.